Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

NCT00900263 · View on ClinicalTrials.gov ↗

Study Summary

RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma may help doctors learn more about changes that occur in DNA and identify biomarkers related to these diseases. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at blood and bone marrow samples from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma.

Interventions

  • GENETIC microarray analysis
  • OTHER biologic sample preservation procedure
  • OTHER laboratory biomarker analysis
  • GENETIC cytogenetic analysis

Study Locations (20)

Kansas

  • Menorah Medical Center — Overland Park
  • Saint Luke's Hospital - South — Overland Park
  • Tammy Walker Cancer Center at Salina Regional Health Center — Salina
  • Shawnee Mission Medical Center — Shawnee Mission
  • Cotton-O'Neil Cancer Center — Topeka

Missouri

  • Saint Luke's Cancer Institute at Saint Luke's Hospital — Kansas City
  • St. Joseph Medical Center — Kansas City
  • North Kansas City Hospital — Kansas City
  • Parvin Radiation Oncology — Kansas City
  • Heartland Hematology Oncology Associates, Incorporated — Kansas City

Arkansas

  • Highlands Oncology Group - Springdale — Bentonville
  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences — Little Rock

Michigan

  • Josephine Ford Cancer Center at Henry Ford Hospital — Detroit
  • Clemens Regional Medical Center — Mount Clemens

Alabama

  • Providence Cancer Center at Providence Hospital — Mobile

California

  • USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles

Illinois

  • Veterans Affairs Medical Center - Hines — Hines

Louisiana

  • Tulane Cancer Center Office of Clinical Research — Alexandria

Trial Details

FieldValue
Enrollment Target 375 participants
Start Date 2002-06

Sponsor

SWOG Cancer Research Network

212 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00900263

The ClinicalTrials.gov registry entry for NCT00900263 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions — of which microarray analysis is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00900263 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Kansas, Missouri, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00900263 about?

NCT00900263 is a clinical study titled "S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma". RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma may help doctors learn more about changes that occur in DNA and identify biomarkers related to these diseases. It may also h...

What is the current status of trial NCT00900263?

This trial is currently completed. The enrollment target is 375 participants. The study started on 2002-06.

What conditions does trial NCT00900263 study?

This clinical trial studies the following conditions: Multiple Myeloma, Plasma Cell Myeloma, Precancerous Condition. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00900263?

The interventions under investigation include: microarray analysis (GENETIC), biologic sample preservation procedure (OTHER), laboratory biomarker analysis (OTHER), cytogenetic analysis (GENETIC). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00900263?

This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00900263 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial